| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.098 | 0.1 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.1 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.23 | 0.1 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.072 | 0.1 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |